Insight Molecular Diagnostics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $11,583 | $8,636 |
| Accounts receivable, net of allowance for credit losses of $11 and $16, respectively | 1,128 | 1,613 |
| Inventories | 446 | 410 |
| Deferred financing costs | — | 279 |
| Restricted cash, current | 729 | — |
| Prepaid expenses and other current assets | 1,420 | 821 |
| Total current assets | 15,306 | 11,759 |
| NONCURRENT ASSETS | ||
| Right-of-use operating and financing lease assets, net | 2,815 | 2,757 |
| Machinery and equipment, net, and construction in progress | 6,435 | 3,567 |
| Intangible assets, net | — | 14,607 |
| Restricted cash, noncurrent | 607 | 1,700 |
| Other noncurrent assets | 593 | 691 |
| TOTAL ASSETS | $25,756 | $35,081 |
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $2,544 | $1,641 |
| Due to related party (Note 9) | 2,780 | 638 |
| Accrued compensation | 2,461 | 1,939 |
| Accrued royalties | 1,116 | 1,116 |
| Accrued expenses and other current liabilities | 939 | 418 |
| Operating and financing lease liabilities, current | 1,807 | 1,295 |
| Contingent consideration liabilities, current | 428 | 228 |
| Total current liabilities | 12,075 | 7,275 |
| NONCURRENT LIABILITIES | ||
| Operating and financing lease liabilities, noncurrent | 1,690 | 2,369 |
| Contingent consideration liabilities, noncurrent | 43,455 | 37,711 |
| TOTAL LIABILITIES | 57,220 | 47,355 |
| Commitments and contingencies (Note 6) | ||
| SHAREHOLDERS’ DEFICIT | ||
| Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, no par value, 230,000 shares authorized; 28,683 and 17,453 shares issued and outstanding at December 31, 2025 and 2024, respectively | 369,211 | 338,244 |
| Accumulated other comprehensive income | 86 | 21 |
| Accumulated deficit | (400,761) | (350,539) |
| Total shareholders’ deficit | (31,464) | (12,274) |
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | $25,756 | $35,081 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.